Lugano/Amsterdam, 28 February 2013 -- A range of new and promising targeted drugs currently under development for improved cancer therapy will be presented during the 11th International Congress on Targeted Anticancer Therapies, Paris, 4-6 March 2013 (TAT 2013). The event, which is organised by NDDO Education Foundation, is an ESMO Partnership Meeting, co-sponsored by the U.S. National Cancer Institute.
Over 500 oncologists and scientists from all over the world will review and discuss cancer therapies of the future. Among them, many top academic experts involved in the early-phase clinical development of new targeted therapeutics and molecular cancer diagnostics, the cornerstones of personalised cancer therapy .
Personalised cancer medicine: targets and therapeutics
The development of new targeted cancer therapies is one of the main drivers for the further evolution of personalized cancer medicine. The concept of personalized medicine is based upon the notion that cancer development and progression are driven by genomic abnormalities and that these abnormalities are different not only between different types of cancer, but also between individual patients. Such findings have opened the door to the development of targeted cancer therapeutics, directed against tumour-specific molecular abnormalities.
At TAT 2013, over 50 plenary lectures and 70 posters will address dozens of emerging targeted agents and new drug targets under development for cancer therapy. In particular targets and experimental therapeutics in the early stages of clinical and the late stages of preclinical development will be addressed.
- Keynote Lecture "Targeting immune checkpoints in cancer therapy" (Michael B. Atkins, Washington, DC);
- "New immune checkpoints as targets", featuring updates on four promising global drug development programmes targeting the immune system in cancer patients;
- "Metabolic drug targets", featuring updates on three major drug development programmes trying to exploit abnormalities in tumour cell metabolism;
- "Phase 1 studies, completed or in progress", featuring seven targeted drugs in phase 1, including brand-new data;
- "Whole-genome sequencing in early-phase drug development", addressing issues around the implementation of genomics already in the early clinical phases of drug development in order to better identify patients that will benefit from the new drug;
- NDDO Honorary Award Lecture 2013 "Phase 1, a critical step for cancer drug development" (Jean-Pierre Armand, Paris, France)
Accepted abstracts can be obtained through the TAT Congress Secretariat[email@example.com] or the ESMO Press Office[firstname.lastname@example.org] prior to verification of the requesting journalist's credentials.
Abstracts are embargoed until March 1, midnight CET, and cannot be made public before that day. Journalists are kindly requested to observe embargoes.
Bona fide journalists representing recognized news agencies, journals, magazine, newspapers, broadcast and online media may request a Complimentary Media Registration by sending an email to the congress management agency[email@example.com]. Journalists must present media credentials and their business card or a copy of their passport. Freelance journalists must, in addition, present a letter of assignment on the letterhead of a recognized news organization.
For further info:
ESMO Press Office
TAT Congress Secretariat